Speaker: Mark Schneiderhan, PharmD, BCPP, Associate Professor, Department of Pharmacy Practice and Pharmaceutical Sciences, UMN College of Pharmacy, and Comprehensive Medication Management (CMM) Provider at Human Development Center (bio)

Learning Objectives: Following the presentation, attendees will be able to:

1. Differentiate tardive dyskinesia (TD) from other common extra-pyramidal side-effects from antipsychotic agents

2. Describe APA practice treatment guidelines and the mechanism of action of VMAT2 inhibitors.

3. Compare and contrast metabolism, dosage administration, and titration of deutetrabenazine (Austedo®) and valbenazine (Ingrezza®)

4. Evaluate a patient case including: mental status, abnormal laboratory or procedures, medications/substances, current/past medical histories when considering starting a VMAT2 inhibitor.

This seminar occurred on November 13, 2023. Please complete this post-seminar survey in order to receive CE.

CE for this seminar will be provided free of charge for our UMN CoP community in order to support continuing professional development. Pharmacists and Pharmacy Technicians: This activity is approved for 1.0 contact hour. To access CE, complete the post-seminar evaluation, linked here. UANs: JA4008105-0000-23-142-H01-P and JA4008105-0000-23-142-H01-T. 

In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The National Center OICPD is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CE Disclosure: As a Jointly Accredited Provider of Interprofessional Continuing Education Credit, the National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD) complies with the ACCME and Joint Accreditors’ Standards for Integrity and Independence in Accredited Continuing Education. The National Center has a conflict of interest policy that requires all individuals involved in the development, planning, implementation, peer review and/or evaluation of an activity to disclose any financial relationships with ineligible companies. The National Center performs a thorough review of the content of the accredited activity to ensure that any financial relationships have no influence on the content of accredited activities. All potential conflicts of interest that arise based on these financial relationships are mitigated prior to the accredited activity.